Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae

被引:120
作者
Rozen, Daniel E.
McGee, Lesley
Levin, Bruce R.
Klugman, Keith P.
机构
[1] Emory Univ, Hubert Dept Global Hlth, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA
[2] Emory Univ, Dept Biol, Atlanta, GA 30322 USA
关键词
D O I
10.1128/AAC.01161-06
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The fitness cost of the genes responsible for resistance to fluoroquinolones in clinical isolates of Streptococcus pneumoniae were estimated in vitro in a common genetic background. Naturally occurring parC, parE, and gyrA loci containing mutations in the quinolone-resistance-determining regions were introduced by transformation into S. pneumoniae strain R6 individually and in combinations. The fitness of these transformants was estimated by pairwise competition experiments with a common R6 strain. On average, single par and gyr mutants responsible for low-level MIC resistance (first-step resistance) impose a fitness burden of approximately 8%. Some of these mutants engender no measurable cost, while one, a parE mutant, reduces the fitness of these bacteria by more than 40%. Most interestingly, the addition of the second par or gyr mutations required for clinically significant, high-MIC fluoroquinolone resistance does not increase the fitness burden imposed by these single genes and can even reduce it. We discuss the implications of these results for the epidemiology of fluoroquinolone resistance and the evolution of acquired resistance in treated patients.
引用
收藏
页码:412 / 416
页数:5
相关论文
共 52 条
[21]   Analysis of topoisomerase function in bacterial replication fork movement: Use of DNA microarrays [J].
Khodursky, AB ;
Peter, BJ ;
Schmidt, MB ;
DeRisi, J ;
Botstein, D ;
Brown, PO ;
Cozzarelli, NR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (17) :9419-9424
[22]   Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae [J].
Kyaw, MH ;
Lynfield, R ;
Schaffner, W ;
Craig, AS ;
Hadler, J ;
Reingold, A ;
Thomas, AR ;
Harrison, LH ;
Bennett, NM ;
Farley, MM ;
Facklam, RR ;
Jorgensen, JH ;
Besser, J ;
Zell, ER ;
Schuchat, A ;
Whitney, CG .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (14) :1455-1463
[23]   LONG-TERM EXPERIMENTAL EVOLUTION IN ESCHERICHIA-COLI .1. ADAPTATION AND DIVERGENCE DURING 2,000 GENERATIONS [J].
LENSKI, RE ;
ROSE, MR ;
SIMPSON, SC ;
TADLER, SC .
AMERICAN NATURALIST, 1991, 138 (06) :1315-1341
[24]  
Levin BR, 2002, NETH J MED, V60, P58
[25]  
LEVIN BR, 1997, CLIN INFECT DIS S1, V24, P9
[26]   Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections [J].
Lindgren, PK ;
Marcusson, LL ;
Sandvang, D ;
Frimodt-Moller, N ;
Hughes, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2343-2351
[27]   The population dynamics of antimicrobial chemotherapy [J].
Lipsitch, M ;
Levin, BR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :363-373
[28]   Changing trends in antimicrobial-resistant pneumococci: It's not all bad news [J].
Low, DE .
CLINICAL INFECTIOUS DISEASES, 2005, 41 :S228-S233
[29]   Fluoroquinolone-resistant pneumococci: Maybe resistance isn't futile? [J].
Low, DE .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (02) :236-238
[30]   Quinolone resistance among pneumococci: Therapeutic and diagnostic implications [J].
Low, DE .
CLINICAL INFECTIOUS DISEASES, 2004, 38 :S357-S362